Teva Climbs as CEO Sees Robust Growth After Allergan DealBy
CEO Vigodman says generic-drug purchase to close ‘at any time’
Adjusted earnings, sales estimates exceed analysts forecasts
Teva Pharmaceutical Industries Ltd. surged the most in a year after Israel’s biggest company presented investors with a rosy picture of the drugmaker’s future, starting with the imminent approval of its $40.5 billion deal with Allergan Plc.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.